

SUPPLEMENTARY TABLE S2. CLINICAL MEASURES FOR THE EDITION 1 AND EDITION 2 SUBSTUDIES
(MODIFIED INTENT-TO-TREAT POPULATION)

	EDITION 1 substudy		EDITION 2 substudy	
	Flexible dosing (n=55)	Fixed dosing (n=53)	Flexible dosing (n=44)	Fixed dosing (n=42)
Daily basal insulin dose (U/kg)				
Baseline of substudy [mean (SD)] ^a	0.98 (0.37)	0.93 (0.39)	1.03 (0.36)	0.93 (0.23)
End of substudy (Month 3) [mean (SD)] ^b	1.01 (0.39)	0.96 (0.43)	1.08 (0.39)	0.97 (0.26)
Baseline of substudy to end of substudy (Month 3) [LS mean change (SE)]	0.04 (0.02)	0.04 (0.02)	0.05 (0.02)	0.03 (0.02)
LS mean difference (95% CI)	0.00 (-0.04 to 0.03)		0.02 (-0.02 to 0.05)	
HbA _{1c}				
Baseline of substudy [mean (SD)] ^a				
% mmol/mol	7.21 (0.91)	7.17 (0.89)	7.41 (0.96)	7.47 (1.05)
End of substudy (Month 3) [mean (SD)] ^b	55.3 (9.9)	54.9 (9.7)	57.5 (10.5)	58.1 (11.5)
% mmol/mol	7.25 (0.96)	7.14 (0.96)	7.47 (0.87)	7.49 (1.11)
Baseline of substudy to end of substudy (Month 3) [LS mean change (SE)]				
% mmol/mol	0.21 (0.11)	0.15 (0.12)	-0.12 (0.15)	-0.25 (0.16)
LS mean difference (95% CI)	2.3 (1.2)	1.6 (1.3)	-1.3 (1.7)	-2.7 (1.8)
FPG				
Baseline of substudy [mean (SD)] ^a				
mg/dL	132.1 (37.6)	121.0 (46.3)	127.5 (33.0)	128.4 (48.8)
mmol/L	7.3 (2.1)	6.7 (2.6)	7.1 (1.8)	7.1 (2.7)
End of substudy (Month 3) [mean (SD)] ^b				
mg/dL	137.2 (42.9)	126.1 (55.0)	132.9 (41.4)	134.0 (39.0)
mmol/L	7.6 (2.4)	7.0 (3.1)	7.4 (2.3)	7.4 (2.2)
Baseline of substudy to end of substudy (Month 3) [LS mean change (SE)]				
mg/dL	25.9 (7.1)	21.0 (7.6)	-8.2 (9.6)	-4.5 (10.2)
mmol/L	1.44 (0.39)	1.17 (0.42)	-0.46 (0.53)	-0.25 (0.57)
LS mean difference (95% CI)				
mg/dL	4.9 (-10.6 to 20.3)		-3.7 (-21.6 to 14.1)	
mmol/L	0.27 (-0.59 to 1.13)		-0.21 (-1.20 to 0.78)	

^aMonth 6 of the main EDITION study.

^bMonth 9 of the main EDITION study.

CI, confidence interval; FPG, fasting plasma glucose; HbA_{1c}, hemoglobin A1c; LS, least squares.